<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">21913063</PMID>
        <DateCompleted>
            <Year>2012</Year>
            <Month>01</Month>
            <Day>05</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1534-6269</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>13</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>2011</Year>
                        <Month>Dec</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Current oncology reports</Title>
                <ISOAbbreviation>Curr Oncol Rep</ISOAbbreviation>
            </Journal>
            <ArticleTitle>PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond.</ArticleTitle>
            <Pagination>
                <MedlinePgn>442-9</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s11912-011-0193-9</ELocationID>
            <Abstract>
                <AbstractText>Poly(ADP-ribose)polymerase (PARP) inhibitors are showing considerable promise for the treatment of BRCA mutation-associated ovarian and breast cancer. This approach exploits a synthetic lethal strategy to target the specific DNA repair pathway in cancers that harbor mutations in the BRCA1 or BRCA2 genes. Accumulating evidence suggests that PARP inhibitors may have a wider application in the treatment of sporadic, high-grade serous ovarian cancers and other cancers including endometrial cancer. In this review, we discuss the clinical development of PARP inhibitors in ovarian cancer and explore challenges that need to be addressed if the full potential of these agents is to be realized.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Banerjee</LastName>
                    <ForeName>Susana</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gynaecology Unit, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK. susana.banerjee@rmh.nhs.uk</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kaye</LastName>
                    <ForeName>Stan</ForeName>
                    <Initials>S</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Curr Oncol Rep</MedlineTA>
            <NlmUniqueID>100888967</NlmUniqueID>
            <ISSNLinking>1523-3790</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000067856">Poly(ADP-ribose) Polymerase Inhibitors</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019398" MajorTopicYN="N">Genes, BRCA1</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D024522" MajorTopicYN="N">Genes, BRCA2</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010051" MajorTopicYN="N">Ovarian Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000067856" MajorTopicYN="Y">Poly(ADP-ribose) Polymerase Inhibitors</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2011</Year>
                <Month>9</Month>
                <Day>14</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2011</Year>
                <Month>9</Month>
                <Day>14</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2012</Year>
                <Month>1</Month>
                <Day>6</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">21913063</ArticleId>
            <ArticleId IdType="doi">10.1007/s11912-011-0193-9</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>J Clin Oncol. 2001 Jul 15;19(14):3312-22</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11454878</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Mol Med. 2008 Jul;22(1):113-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18575783</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Cancer. 2004 Oct;4(10 ):814-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15510162</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2010 Apr 15;16(8):2344-51</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20371688</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2010 Dec 15;16(24):6159-68</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20802015</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>EMBO Mol Med. 2009 Sep;1(6-7):315-22</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20049735</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2008 Dec 1;26(34):5530-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18955455</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2010 Aug 1;28(22):3555-61</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20547991</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cell Biol. 2002 Jan;22(2):669-79</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11756561</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2002 Jan 15;20(2):463-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11786575</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>BMC Cancer. 2008 Jan 22;8:17</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18208621</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>JAMA. 2000 May 3;283(17):2260-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10807385</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Clin Oncol. 2010 Sep;7(9):508-19</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20700108</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2010 Aug 1;28(22):3570-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20606085</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2005 Apr 14;434(7035):913-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15829966</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2007 May 1;13(9):2728-37</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17473206</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cell. 1998 Feb;1(3):347-57</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9660919</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2009 Jul 9;361(2):123-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19553641</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Cancer. 2005 Sep;5(9):689-98</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16110319</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biochem Biophys Res Commun. 2006 Nov 17;350(2):352-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17007818</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2008 Aug 1;26(22):3785-90</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18591545</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2008 Feb 28;451(7182):1111-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18264088</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2000 Jul;6(7):2860-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10914735</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2011 Jan 20;364(3):205-14</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21208101</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Sci Transl Med. 2010 Oct 13;2(53):53ra75</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20944090</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Natl Cancer Inst. 2004 Jan 7;96(1):56-67</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14709739</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>EMBO J. 2001 Sep 3;20(17):4704-16</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11532935</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2010 May 20;28(15):2512-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20406929</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2000 Oct 1;60(19):5329-33</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11034065</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2005 Apr 14;434(7035):917-21</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15829967</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet. 2010 Jul 24;376(9737):245-51</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20609468</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Eur J Cancer. 2007 Sep;43(14 ):2124-33</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17714938</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2001 May 17;411(6835):366-74</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11357144</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
